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Abstract
Background: The objectives of this study were to compare the prevalence and quality of life (QOL) of irritable
bowel syndrome (IBS) in women with polycystic ovary syndrome (PCOS) compared with healthy women.
Methods: This was a case-control study of 201 women recruited at an infertility clinic in Iran. The control group
were healthy women (n = 100) and the comparison group, women with PCOS (n = 101). Data were collected by
clinical Rome III criteria to determine the IBS, Bristol scale for stool consistency and IBS QOL.
Results: The reporting of IBS symptoms were higher in PCOS (20.7%) than control group (11%) (P = 0.05). The IBS
QOL score in the IBS + PCOS group was lower than other groups (IBS+ non PCOS, non IBS + PCOS, non IBS+ non
PCOS; scores in food avoidance and worries about health domains were significant (P < 0.01).
Conclusions: We conclude that having PCOS and an increased level of LH/FSH tends to cause IBS symptoms. IBS +
PCOS women experience significant impaired quality of life scores particularly in relation to worries about health
and food avoidance. These results offer further insights into IBS in PCOS women and their functional status and
wellbeing.
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Introduction
Irritable bowel syndrome (IBS) is one of the most com-
mon disorders of the digestive system, with a 10–20% in-
cidence globally [1]. People with IBS have sensitive
intestines and suffer from intestinal muscle spasms in re-
sponse to food, gas, and stress. These spasms can lead to
abdominal cramps and pains, changes in bowel function,
bloating, diarrhoea, and constipation [2]. Patients with IBS
also experience higher rates of absence from work, disrup-
tion of interpersonal relations, including a reluctance to
have sexual intercourse. IBS can prevent patients from at-
tending social gatherings and travelling for fear of experi-
encing symptoms in public. Many studies have reported a
lower level of the quality of life (QOL) for these patients
than the general population [3–6].
Although studies have shown that the prevalence of
IBS in women is twice that of men generally, it was be-
lieved that this disorder was lower in women with PCOS
compared to healthy women. However a recent study re-
ported an increased prevalence of IBS in women with
PCOS compared to healthy women [7]. Polycystic ovar-
ian syndrome (PCOS) is a common chronic endocrine
disease which affects 5–10% of women of reproductive
age. It is characterized by chronic anovulation, with
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clinical or laboratory signs of hyperandrogenism [8].
Obesity is prevalent in women with PCOS due to ele-
vated androgen levels [9]. However, there is no detailed
description of the relationship between IBS and women
with PCOS symptoms in relation to raised androgen
levels and raised body mass index (BMI) [7].
These factors influenced the decision to investigate the
prevalence of IBS in women with PCOS compared to
healthy women and to compare QOL in a group of
women with PCOS and healthy women.
Methods
Design and data collection
This was a case-control study of women with PCOS
who attended an infertility clinic at a hospital in Hor-
mozgan Province, Iran from May to September 2014.
This clinic is the only referral center for infertility in the
province. The sample size (201) was calculated using
Mathur, et al., (2010) information. Women with a con-
firmed diagnosis of PCOS (n = 300) were invited to par-
ticipate in the study as a case comparison group. After
explaining the study objectives and obtaining written
consent from each woman, final participants were ran-
domly allocated to the PCOS (n = 101); a control group
of healthy women whose partners had a diagnosis of
male infertility (n = 100) were approached in the same
way. Inclusion criteria were include being 15–40 years of
age [10–17]; married; absence of non-classic adrenal
hyperplasia, thyroid dysfunction, hyperprolactinemia;
non-smoking; absence of following warning signs that
rejected IBS included extreme weight loss over the past
few months, fever, nocturnal symptoms, severe chronic
constipation, diarrhea, frequent vomiting, progressive
dysphasia, a history of travel to areas of parasitic infec-
tions, family history of colon cancer, inflammatory bowel
disease; not having cough (bronchitis) during the last 3
months; no problems in speaking or listening; Iranian;
not taking any prescription medication (except allergy
medications and occasional pain medications) for at least
3 months before entering the study; having two of the
following Rotterdam diagnostic criteria:
1) Polycystic ovaries visualized on ultrasound scan
(presence of 12 follicles or more in one or both
ovaries and/or increased ovarian volume i.e., > 10ml),
2) Clinical signs of hyperandrogenism (hirsutism score
based on hirsutism score greater than 7 or obvious
acne),
3) having an interval between menstrual periods > 35
days and/or amenorrhea, defined as the absence of
vaginal bleeding for at least 6 months (i.e. 199 days).
The women were requested to complete the study
measures in clinic.
Measures
1. Menstrual history: all women were asked for the
interval between menstrual periods during the
preceding 12 months; results were categorized to <
21 days, 21–34 days, 35–60 days (oligomenorrhea),
> 199 days (amenorrhea) and variable.
2. BMI: weight and height were calculated by weight/
height squared [kg/m2] in all women.
3. Body hair: Clinical assessment of hirsutism in all
women was determined using the Ferriman-
Gallwey Scoring System (F/G score). Nine body
sites (the upper lip, chin, chest, upper back, lower
back, upper abdomen, lower abdomen, arm, and
thigh) were graded from 0 (no terminal hair) to 4
(severe hirsutism). Scores can range from zero to
36. A score of seven or above was considered posi-
tive for hirsutism [18].
4. Acne: the Global Acne Grading System (GAGS)
was used to determine acne in all women. The
GAGS assesses six locations on the face and chest/
upper back, calculating surface area, distribution,
and density of pilosebaceous units of lesions. Each
of the six locations is graded separately on a scale
0-to-4, with the most severe lesion within that loca-
tion determining the local score. The global score is
a summation of all local scores [19].
5. Socio-demographic status: The study used years of
formal education as a measure of socioeconomic
status, categorized into five levels: no education,
first level (1 to 5 years), second level (6–9 years),
third level (10–12 years) and fourth level (more
than 12 years). Donyavi et al., (2011) show that
education is a good proxy measure for
socioeconomic status for Iranians.
6. Laboratory measures: An overnight or 8 h fasting
venous blood sample was obtained from each
patient. Follicle-stimulating hormone (FSH) and
Luteinizing hormone (LH) were assessed in all par-
ticipants by ELIZA (DRG Instruments GmbH, Mar-
burg, Germany).
7. ROME III diagnostic criteria: since IBS has no
structural disorder or biochemical signs, the
diagnosis is based on clinical signs. The ROME III
criteria for the diagnosis of IBS (2006) includes
intermittent abdominal pain on at least 3 days of
the month in the last 3 months with at least two of
the following three criteria combined: (i) abdominal
pain or discomfort improves with defecation, (ii)
abdominal pain or discomfort starts with a change
in frequency of defecation, (iii) abdominal pain or
discomfort start with a change in stool consistency
(appearance). It should be noted that the above
criteria must be present in the last 3 months before
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the diagnosis, as well as at least last 6 months from
the onset of symptoms. The validity and reliability
of these tools are approved in Iran [20].
8. IBS-QOL questionnaire was designed by Patrick,
et al., (1998) and contains 34 items with a five
degree Likert scale. There are eight domains:
dysphoria, relationships, sexual concern, health
worry, social reaction, body image, food avoidance,
and interference with activity. Scores were between
0 to 100; a higher score in this tool represents a
worse quality of life [21]. The validity and reliability
of these tools are approved in Iran.
9. Bristol scale stool consistency: Bristol stool form
scale is a medical aid designed to classify the form
of human feces into seven categories including type
1: Separate hard lumps, like nuts (hard to pass);
type 2: sausage-shaped, but lumpy; type 3: like a
sausage but with cracks on its surface; type 4: like a
sausage or snake, smooth and soft; type 5: soft blobs
with clear cut edges (passed easily); type 6: fluffy
pieces with ragged edges, a mushy stool; type 7:
watery, no solid pieces, entirely liquid. Types one
and two indicate constipation, with three and four
being the ideal stools (especially the latter), as they
are easy to defecate while not containing excess li-
quid, and five, six and seven tending towards diar-
rhea [22].
Statistical analysis
Data were presented as mean ± Standard Deviation (SD)
and frequency (percent) for quantitative and qualitative
variables, respectively. Pearson Chi square test was used
to compare demographic variables in the two groups.
Ordinal demographic variables were compared between
the two groups using the Mann-Whitney U test. Inde-
pendent samples t-test was used to compare the means
of in two groups.
Ethical considerations
The Ethics Committee of the Hormozgan Medical Uni-
versity reviewed the study.
Results
The study sample
Over a period of 6 months, 201 women were recruited
to the study. The socioeconomic and clinical characteris-
tics of patients are presented in Table 1. There was a sig-
nificant difference between the two groups in terms of
PCOS related features (such as acne, hirsutism and men-
strual pattern and LH/FSH ratio) (P < 0.001).
IBS subtype & stool frequency
IBS cases in women with PCOS was 29.7% and the con-
trol group 11% (P < 0.01). The highest number of PCOS
women placed in subtype of IBS – Constipation (20.8).
According to Bristol stool consistency scale, women were
in 2 rd and 3rd rank (sausage-shaped, but lumpy; and like
a sausage but with cracks on its surface, respectively) that
matches with IBS-Constipation relatively (Table 2).
Comparison of sum scores of IBSQOL
There was significant difference in QOL scores between
two groups (P < 0.001) mainly in food avoidance and
worries about health (Table 3). In other word, in PCOS






Age (year) 28 ± 4.92 29.68 ± 5.36 0.02
Education (year) 11.74 ± 3.53 10.77 ± 3.84 0.06
BMI 25.52 ± 4.70 24.53 ± 3.88 0.1
Occupation
Occupied 18 19 0.82
Housewife 83 81
Parity 0.16 ± 0.42 0.15 ± 0.35 0.74
Menstruation
< 21 2 (1.98) 2 (2) < 0.001
21–35 34 (33.66) 79 (79)
35–60 17 (16.83) 6 (6)
> 3 month 7 (6.93) 1 (1)
Variable 41 (40.59) 12 (12)
Hirsutism score 3.35 ± 3.15 0.58 ± 1.39 < 0.001
Acne score 4.20 ± 5.01 1.76 ± 3.8 < 0.001
LH/FSH 1.88 ± 1.52 0.93 ± 1.21 < 0.001








No IBS 71 (70.3) 89 (89) 0.002
IBS-C 21 (20.8) 5 (5)
IBS-D 4 (4) 2 (2)
IBS-M 5 (5) 4 (4)
Bristol scale stool consistency
0 71 (70.3) 89 (89) < 0.001
1 4 (4) 2 (2)
2 7 (6.9) 3 (3)
3 10 (9.9) 3 (3)
4 5 (5) 1 (1)
5 2 (2) 1 (1)
6 2 (2) 1 (1)
7 – –
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patients the lowest scores of QOL were belong to IBS
subgroup. Similarly, in control group the lowest scores
of QOL were belong to IBS subgroup. Moreover, the
IBS+ PCOS patients had lower QOL scores than IBS+
non PCOS patients.
Discussion
In this study, IBS cases in patients with PCOS (29.7%)
by using Rome III criteria is higher than the values re-
ported in the general population. Mathur et al. (2010)
have also reported the IBS prevalence 41.7% by criteria
Rome I in women with PCOS. Several studies in Iran
have also reported the prevalence of IBS in different
populations. The prevalence of IBS in Iranian blood do-
nors was 5.6% [23]. The prevalence of IBS in 18,180
people in five cities in Tehran province was estimated to
be about 1% by employing Rome III criteria [24]. Several
issues may contribute to such the wide range reported in
these studies which use different diagnostic criteria for
IBS. Rome III is less restrictive then Rome II which de-
mands patients to report their symptoms over longer pe-
riods. Compared to Rome III, a higher number of
patients self diagnose with IBS using Rome II. Therefore,
it’s seemed that the prevalence estimated by Rome III is
lower than Rome II and I [25]. proposes using Rome III
criteria in studies. Moreover, the role of socioeconomic
status and cultural differences should be taken into ac-
count. Ho et al., 1998 suggested that the IBS in the
urban group more than rural probably because the
urban group reported a significantly greater influence of
stress than the rural group. It is believed that the preva-
lence of IBS is less in developing countries (like Iran)
compared to western countries [26, 27].
Increased levels of ovarian hormones decrease gastro-
intestinal transit [28]. Therefore women with IBS report
the symptoms related to constipation more than men,
except at the time of menstruation when hormone levels
have reduced [29]. In the present study, the majority of
patients with PCOS (20.8%) have IBS dominant consti-
pation (IBS-C). It seems the cause of this variant of IBS
is due to the high levels of hormones in PCOS which
interference with bowel function. However, if only the
hyper-androgenic condition is involved in the increased
risk of IBS, it might be expected that IBS cases in the
PCOS group should be less than the control groups.
Stress can affect the gastrointestinal function, so that
the start and the severity of the symptoms of IBS are re-
lated to acute and chronic stress. Therefore, patients
with IBS have hyperactivity to stress (excessive response
of limbic system to the stress) [30]. A history of adverse
life events and stress cause changes in the hypothal-
amic–pituitary–adrenal axis response to stress and






IBS No IBS IBS No IBS
Overall 60.71 ± 13.30 99.46 ± 2.98 74.13 ± 20.92 98.40 ± 6.02 < 0.001
P valuea < 0.001 < 0.001
Dysphoria 61.30 ± 13.94 99.64 ± 2.96 75.94 ± 2.77 99.39 ± 6.04 < 0.001
P value < 0.001 < 0.001
Interference with activity 60.83 ± 12.96 99.64 ± 2.96 74.02 ± 20.70 98.35 ± 6.16 < 0.001
P value < 0.001 < 0.001
Relationship 61.38 ± 12.58 99.64 ± 2.96 75 ± 23.27 98.04 ± 6 < 0.001
P value < 0.001 < 0.001
Sexual 61.66 ± 14.28 99.64 ± 2.96 76.13 ± 12.97 98.31 ± 6.30 < 0.001
P value < 0.001 < 0.001
Health worry 60.05 ± 13.79 99.64 ± 2.98 73.48 ± 21.02 98.59 ± 5.78 < 0.001
P value < 0.001 < 0.001
Food avoidance 59.72 ± 13.80 99.64 ± 2.96 70.45 ± 21.20 98.31 ± 6.30 < 0.001
P value < 0.001 < 0.001
Social reaction 61.85 ± 13.36 99.64 ± 2.96 75 ± 21.83 98.52 ± 5.80 < 0.001
P value < 0.001 < 0.001
Body image 61.66 ± 13.90 99.64 ± 2.96 73.29 ± 20.17 98.31 ± 6.30 < 0.001
P value < 0.001 < 0.001
aBetween IBS and no IBS in PCOS / control groups, separately
bBetween PCOS and control groups with IBS
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inappropriate signaling of Corticotropin-releasing hor-
mone as the most important factor in the increased
prevalence of IBS [31]. Previous studies have reported
that women with PCOS have more anxiety and stress
which may cause a higher prevalence of IBS in these pa-
tients [32]. In addition to PCOS, an increase in the
amount of LH/FSH was also an important predictor
variable of IBS. In women with PCOS, the LH/FSH ratio
was higher and it seems that an increase the perceived
stress by patients may lead to increased sensitivity of the
hypothalamic–pituitary–adrenal axis and LH and conse-
quently a higher prevalence of IBS in these patients. Use
of gonadotropin releasing hormone analogue leuprolide
acetate which dramatically decreases LH which would be
improves of chronic abdominal pain in women [33]..
IBS has a strong effect on the quality of life in women
are diagnosed with it as it imposes substantial social and
economic costs due to the need for medical care and ab-
senteeism at work. One study in Iran investigated the
economic burden of IBS and showed the cost of IBS in
Iran about 2.8 million dollars and this is of great signifi-
cant for Iranian population [34].
There are no specific biomarkers to assess the condi-
tion of patients with IBS. Thus there needs to be in-
creased attention to the non-pathological markers in
evaluating the impact of IBS as a chronic disease on well
being, daily functioning and QOL. According Frank
et al., 2002) patients with IBS have poor QOL compared
to the general population; the same authors emphasize
that IBS has a greater negative impact on QOL than
asthma, gastroesophageal reflux disease (GERD) or mi-
graine headaches. In the present study, QOL in women
with IBS in both groups was significantly lower than in
women without IBS. In both groups, worries about
health and food avoidance were the areas of QOL most
affected by IBS. Sung Kim et al. (2010) reported that the
most affected areas were dysphonia, worries about health
and the food avoidance [35]. These findings suggests that
in our patients like Korean female with IBS, IBS patients
suffer more from anxiety about their disease than impair-
ment of social activity or relationship by bowel symptom.
Studies on women with PCOS using an IBS specific
QOL tools have not been found identified in the literature;
our study is the first to use IBS specific QOL measures in
women with PCOS compared to healthy women. Studies
using SF36 [36] and WHOQOL [37] to measure QOL
minimize the influence of gastrointestinal symptoms on
general QOL. Specific QOL tools associated with IBS have
been designed and validated and include specific areas as-
sociated with QOL most affected by IBS.
Limitations
There are some limitations in our study. The study
population is from a limited region of Iran and is not be
representative of the general population either in Iran or
other countries. Moreover, there are unmeasured covari-
ates that may play an important role in the association
between IBS and PCOS, for example, psychological his-
tory; that IBS was self-indentified may be another
limitation.
Conclusion
As the results of this study show, having PCOS and an
increased level of LH/FSH might cause IBS. IBS + PCOS
patients experience significant effects on QOL particu-
larly in relation to worries about health and food avoid-
ance. These data offer insights for clinicians into IBS in
women with PCOS and their functional status and
wellbeing.
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